Physician profile
Eric Eugene Belin
NPI 1134105042
$5,461.38
in general payments reported to CMS, 2019-2025
24 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $557 · 2021: $611 · 2022: $972 · 2023: $780 · 2024: $1,131 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.64 |
| Education | $179.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,344.63 | 2020-2025 | Tremfya |
| Abbvie INC. | $861.93 | 2019-2025 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $818.13 | 2019-2025 | |
| Lilly USA, LLC | $457.05 | 2019-2025 | Taltz, Ebglyss |
| Genzyme Corporation | $386.11 | 2021-2025 | |
| Ucb, INC. | $242.84 | 2020-2025 | Bimzelx |
| Pfizer INC. | $225.48 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $142.94 | 2021-2024 | Dupixent |
| Galderma Laboratories, L.P. | $133.20 | 2019-2025 | Nemluvio |
| Dermavant Sciences, INC. | $118.02 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $103.68 | 2023-2024 | Sotyktu |
| Depuy Synthes Sales INC. | $93.66 | 2019 | |
| Dermira, INC. | $68.14 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $66.14 | 2021-2025 | |
| Organon LLC | $63.21 | 2025 | Nexplanon, Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $62.69 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $58.88 | 2020 | |
| Leo Pharma INC. | $56.59 | 2023-2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.49 | 2019-2020 | |
| Amgen INC. | $37.13 | 2020-2021 | |
| Dexcom, INC. | $28.07 | 2025 | Dexcom G6 Transmitter |
| Janssen Scientific Affairs, LLC | $16.87 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Celgene Corporation | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Belin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.